Dynamic urinary proteomic analysis in a Walker 256 intracerebral tumor model

Area of Science:

• Proteomics
• Biomarker Discovery
• Oncology

Background:

• Primary and metastatic brain cancers have poor prognoses due to late diagnosis.
• Urine is an ideal biomarker source for early disease detection as it reflects sensitive, early changes.
• Urine analysis offers potential for early-stage disease information.

Purpose of the Study:

• To investigate early urinary proteome changes in a rat model of intracerebral brain tumors.
• To assess the utility of urine biomarkers for early brain cancer detection.
• To compare urinary proteomic patterns across different tumor models and inoculation sites.

Main Methods:

• An intracerebral Walker 256 (W256) cell injection rat model was established to mimic brain tumor growth.
• Urine samples were collected at 3, 5, and 8 days post-injection.
• Liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) was used for urinary proteome analysis.

Main Results:

• Significant changes in 9 urinary proteins were observed by day 3 and 5, prior to MRI detection.
• By day 8, when tumors were MRI-detectable, 25 differential proteins were identified, including 10 linked to brain tumors.
• Distinct urinary proteomic patterns emerged between intracerebral and subcutaneous tumor models.

Conclusions:

• Early-stage urinary proteome alterations can be detected in an intracerebral brain tumor model.
• The urinary proteome differentiates tumors based on cell type and inoculation site (brain vs. subcutis).
• Urinary proteomic analysis shows promise for early brain cancer detection and characterization.